Literature DB >> 31463892

Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma.

Masataka Nishikawa1, Atsushi Goshima2, Hajime Owaki2, Takeshi Fuji2.   

Abstract

Entities:  

Year:  2019        PMID： 31463892     DOI： 10.1007/s40261-019-00846-w

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  15 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Alan N Baer; Jemima Albayda; Rebecca L Manno; Uzma Haque; Evan J Lipson; Karen B Bleich; Ami A Shah; Jarushka Naidoo; Julie R Brahmer; Dung Le; Clifton O Bingham
Journal:  Ann Rheum Dis       Date:  2016-06-15       Impact factor: 19.103

Review 3.  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

Authors:  Thomas K Eigentler; Jessica C Hassel; Carola Berking; Jens Aberle; Oliver Bachmann; Viktor Grünwald; Katharina C Kähler; Carmen Loquai; Niels Reinmuth; Martin Steins; Lisa Zimmer; Anna Sendl; Ralf Gutzmer
Journal:  Cancer Treat Rev       Date:  2016-02-18       Impact factor: 12.111

4.  Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases.

Authors:  Leonard Calabrese; Vamsidhar Velcheti
Journal:  Ann Rheum Dis       Date:  2016-08-26       Impact factor: 19.103

5.  Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis.

Authors:  Timothy Shun Him Kwok; Mary Jane Bell
Journal:  BMJ Case Rep       Date:  2019-02-27

6.  Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Authors:  Sang Taek Kim; Jean Tayar; Van Anh Trinh; Maria Suarez-Almazor; Salvador Garcia; Patrick Hwu; Daniel Hartman Johnson; Marc Uemura; Adi Diab
Journal:  Ann Rheum Dis       Date:  2017-08-22       Impact factor: 19.103

Review 7.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

8.  Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.

Authors:  Rakiba Belkhir; Sébastien Le Burel; Laetitia Dunogeant; Aurélien Marabelle; Antoine Hollebecque; Benjamin Besse; Alexandra Leary; Anne-Laure Voisin; Clémence Pontoizeau; Laetitia Coutte; Edouard Pertuiset; Gaël Mouterde; Olivier Fain; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2017-06-09       Impact factor: 19.103

9.  Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire.

Authors:  T Pincus; J A Summey; S A Soraci; K A Wallston; N P Hummon
Journal:  Arthritis Rheum       Date:  1983-11

10.  Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review.

Authors:  Ammar Haikal; E Borba; Taqui Khaja; Gary Doolittle; Paul Schmidt
Journal:  Avicenna J Med       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.